PRODUCT

Orforglipron

No short description available.

Research Indications

Weight Loss

moderate

Obesity Management Without Diabetes
ATTAIN-1 Phase 3 trial demonstrated 12.4% weight loss (27.3 lbs) at 72 weeks with 36mg dose in non-diabetic obese individuals. 59.6% achieved ≥10% weight loss, 39.6% achieved ≥15% weight loss. Superior to all existing oral obesity medications.
Obesity Management With Type 2 Diabetes
ATTAIN-2 Phase 3 trial showed 10.5% weight loss in patients with both obesity and diabetes. 72.8% achieved clinically meaningful ≥5% weight loss, demonstrating efficacy maintained in metabolically complicated patients.
Cardiometabolic Risk Factor Improvement
Significant improvements in waist circumference, systolic blood pressure (8-12 mmHg reductions), triglycerides (-20-30%), and non-HDL cholesterol across Phase 3 trials. Comprehensive metabolic syndrome reversal.
Prediabetes Prevention
Among 1,127 ATTAIN-1 participants with prediabetes at baseline, up to 91% achieved near-normal blood sugar levels vs 42% with placebo, demonstrating diabetes prevention potential.

Diabetes

effective

Early Type 2 Diabetes Management
ACHIEVE-1 Phase 3 trial showed HbA1c reductions of 1.3-1.6% from 8.0% baseline over 40 weeks. 76.2% of patients achieved HbA1c u003c7%, 66.0% achieved ≤6.5%, positioning orforglipron as potential first-line oral therapy.
Insulin Resistance Improvement
Significant improvements in insulin sensitivity indices and fasting glucose reduction observed within 4 weeks of therapy initiation. Glucose-dependent mechanism prevents hypoglycemia risk in non-diabetic patients.
Beta Cell Function Preservation
GLP-1R agonism protects pancreatic beta cell function through multiple mechanisms including reduced glucotoxicity, enhanced glucose-responsive insulin secretion, and potential anti-apoptotic effects.
Long-term Glycemic Durability
Biased agonism profile favoring G protein over β-arrestin may reduce receptor desensitization, potentially improving sustained glycemic control compared to peptide GLP-1 agonists. Long-term studies ongoing.

Cardiovascular

effective

Cardiovascular Risk Marker Reduction
Significant improvements in blood pressure (systolic reductions 8-12 mmHg), triglycerides (-20-30%), HDL cholesterol increases, and reductions in small dense LDL particles observed across Phase 3 trials.
Obesity-Related Comorbidity Management
Being investigated for obstructive sleep apnea and hypertension in adults with obesity. GLP-1 class effects suggest potential benefits for cardiovascular event reduction, pending dedicated outcomes trials.
Metabolic Syndrome Reversal
Comprehensive improvements in all five metabolic syndrome criteria (waist circumference, blood pressure, triglycerides, HDL cholesterol, fasting glucose) demonstrated in clinical trials.

Interactions

Semaglutide

Avoid Combination

Both are GLP-1 agonists - combining increases risk of severe hypoglycemia and excessive GI side effects including intractable nausea and vomiting

Tirzepatide

Avoid Combination

Dual GIP/GLP-1 agonist overlaps with GLP-1 mechanism - combination contraindicated due to additive hypoglycemic effects and severe GI toxicity

Liraglutide

Avoid Combination

Another GLP-1 agonist - concurrent use contraindicated due to overlapping mechanisms and compounded adverse effects

Insulin

Monitor Combination

Orforglipron enhances insulin sensitivity - may require significant insulin dose reduction to prevent hypoglycemia, requires close monitoring

Metformin

Synergistic

Complementary mechanisms for diabetes management - Phase 3 trials combining orforglipron with metformin showed enhanced efficacy without increased adverse events

Dapagliflozin

Compatible

SGLT-2 inhibitor with distinct mechanism - combination being evaluated in Phase 3 ACHIEVE-2 trial for potential additive metabolic benefits

CJC-1295

Compatible

Growth hormone secretagogue may help preserve lean muscle mass during GLP-1-induced weight loss without interaction concerns

Ipamorelin

Compatible

May help maintain metabolic rate and muscle preservation during caloric restriction from orforglipron therapy

BPC-157

Compatible

No known interactions - may theoretically support gut health and potentially mitigate GI side effects common with GLP-1 agonists

5-Amino-1MQ

Compatible

NNMT inhibition mechanism is distinct from GLP-1 pathway - may complement metabolic effects for enhanced optimization

Orforglipron

Resources

Categories

Company